Brought to you by 
NovellusDx licenses cancer diagnostics technology from the Gene Editing Institute
06 Sep 2017
Executive Summary
To support its work in the cancer diagnostics space, NovellusDx licensed a gene editing technology from the Gene Editing Institute, part of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NovellusDx licenses cancer diagnostics technology from the Gene Editing Institute
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice